p38MAP激酶抑制剂 | 219138-24-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: p38MAP激酶抑制剂
• 英文名称: 2-(4-chlorophenyl)-4-(fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one
• 英文别名: p38 MAP Kinase Inhibitor；2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1H-pyrazol-3-one
• CAS: 219138-24-6
• 化学式: C₂₀H₁₃ClFN₃O
• 分子量: 365.794
• InChiKey: DZFBYHUKZSRPHU-UHFFFAOYSA-N

物化性质

• 沸点：
  534.1±60.0 °C(Predicted)
• 密度：
  1.388±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：5 mg/ml； DMSO：5 mg/ml； DMSO:PBS(pH7.2)(1:1)：0.5mg/ml；乙醇：0.3 mg/ml

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  对氟苯乙酸乙酯 在 草酰氯 、 二甲基亚砜 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 甲苯 为溶剂， 生成 p38MAP激酶抑制剂
  参考文献：
  名称：

  Pyrroles and other heterocycles as inhibitors of P38 kinase

  摘要：

  Investigation of furans, pyrroles and pyrazolones identified 3-pyridyl-2,5-diaryl-pyrroles as potent, orally bioavailable inhibitors of p38 kinase. 3-(4-pyridyl-2-(4-fluoro-phenyl)-5-(4-methylsulfinylphenyl)-pyrrole (L-167307) reduces secondary paw swelling in the rat adjuvant arthritis model: ID50 = 7.4 mg/kg/b.i.d. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00495-8

文献信息

• Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
  申请人：Chatterjee-Kishore Moitreyee

  公开号：US20060252045A1

  公开（公告）日：2006-11-09

  The invention discloses compositions, compounds, apparatuses and methods of using them to study bone mineralization and identify agents that regulate bone mineralization. Methods of using bone mineralization gene profiles and signatures for compound screening and research are also disclosed. Reagents for modulating bone mineralization are provided for both therapeutic and research usage.

  本发明揭示了用于研究骨矿化和鉴定调节骨矿化的药物的组合物、化合物、装置和使用方法。还揭示了使用骨矿化基因谱和签名进行化合物筛选和研究的方法。提供了用于调节骨矿化的试剂，可用于治疗和研究。
• Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
  申请人：Novartis AG

  公开号：EP2428210A1

  公开（公告）日：2012-03-14

  The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.

  本发明提供了治疗青光眼的组合物和方法、诊断青光眼的方法以及鉴定可能有助于治疗青光眼的制剂的方法。更具体地说，本发明描述了调节血清淀粉样蛋白 A 表达的制剂的用途。
• NOVEL ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS
  申请人：Atriva Therapeutics GmbH

  公开号：EP3708156A1

  公开（公告）日：2020-09-16

  The present invention relates to MEK inhibitor, p38 inhibitor and/or NFκB inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. In addition an in vitro test system, wherein the test system comprises cultured cells infected with an influenza virus and a bacterium or with a bacterium alone is provided.

  本发明涉及MEK抑制剂、p38抑制剂和/或NFκB抑制剂，用于预防和/或治疗由细菌感染和流感病毒感染或单纯细菌感染组成的合并感染的方法。还提供了包含此类抑制剂的组合物，用于预防和/或治疗由细菌感染和流感病毒感染或单纯细菌感染组成的合并感染。此外，还提供了一种体外测试系统，其中测试系统包括感染流感病毒和细菌或仅感染细菌的培养细胞。
• P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
  申请人：Fulcrum Therapeutics, Inc.

  公开号：US10342786B2

  公开（公告）日：2019-07-09

  The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.

  本发明公开了包括 p38 激酶抑制剂和调节 DUX4 及下游基因（包括但不限于 ZSCAN4、LEUTX、PRAMEF2、TRIM43、MBD3L2、KHDC1L、RFPL2、CCNA1、SLC34A2、TPRX1、PRAMEF20、TRIM49、PRAMEF4、PRAME6、PRAMEF15 或 ZNF280A）表达的制剂在内的方法和组合物。本研究公开了用于治疗与 DUX4 及下游基因表达异常有关的疾病（如筋膜囊性肌营养不良症）的方法。
• Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
  申请人：Race Oncology Ltd.

  公开号：US10548876B2

  公开（公告）日：2020-02-04

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

  本发明描述了通过提高单一疗法的疗效或减少副作用来改善以前因治疗效果不理想而受到限制的治疗剂的疗效的方法和组合物。这些方法和组合物尤其适用于双蒽或其衍生物、类似物或原药。